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Abstract The automated delivery of psychological treatment using virtual reality (VR) has the
potential to revolutionise patient access to evidence-based care. VR creates immersive, inter-
active computer simulations, which elicit responses similar to the real world. VR simulations
provide an ideal opportunity for the experimentation and experiential learning that are key to
successful cognitive therapy. If automated, and using the latest consumer kit, VR treatment can
substantially scale-up the delivery of psychological therapy. However, the successful application
of automated VR to mental health difficulties requires precise treatment targets linked to the
right psychological theory and techniques. This paper describes the process of development of
an automated VR cognitive therapy targeting anxious avoidance of everyday social situations
by patients with psychosis. In the gameChange project, a person-centered design process was
used involving people with lived experience of psychosis, clinical psychologists, designers, and
software developers. The six-session gameChange VR therapy consists of six everyday scenarios:
a street, a bus, a café, a pub, a doctor’s waiting room, and a shop. Each scenario has five levels
of difficulty. Every level provides an opportunity to test out fearful cognitions while limiting the
use of safety-seeking behaviours, allowing patients to build confidence in their ability to 
cope. Learning is facilitated by a virtual coach and therapeutic gaming elements are 
included. Data from user testing indicates that the gameChange VR therapy is easy to use and 
engaging. The clinical effectiveness of gameChange VR therapy is now being tested in a 

























































































irtual Reality (VR) could revolutionise the delivery of
owerful psychological treatments. The automation of
vidence-based treatments using VR could allow services to
ubstantially scale up the provision of effective psycholog-
cal therapy. If an automated treatment is shown to work
ell in clinical trials, then there can be confidence in the
utcomes when implemented in clinical services. But how
est is an automated VR psychological treatment devel-
ped? This paper describes the development process for
ameChange (www.gameChangeVR.com), an automated VR
ognitive therapy targeting the highly prevalent anxious
ocial avoidance in psychosis.
R for mental health disorders
R is a term often used very broadly. We use it to describe
hree-dimensional computer simulations of environments
hat can be navigated around and interacted with (we do
ot use it, for example, to describe the viewing of 3D film).
ir-tual environments can elicit similar cognitive and
motional responses to their real world counterparts (e.g.
artens, Antley, Freeman, Slater, Harrison & Tunbridge,
019). It is therefore possible to enter virtual replicas of
roubling situations and make new learning through the use
f spe-cific psychological techniques. Using VR in this way
as a number of advantages. It allows full control over the
nvi-ronment. Situations can be entered repeatedly and
he difficulty graded. Specific stimuli, or scenarios of
herapeu-tic value, can be embedded in the simulations to
ncrease the potency of the experience. Similarly, the
reatment can be made much more engaging than
raditional therapies, and tasks can be designed to increase
he sense of reward and achievement. Furthermore,
lthough VR elicits simi-lar emotions to the real world,
eople are aware that the situations are not real. This
rovides a substantial benefit for psychological treatment:
atients are more willing to enter challenging situations
nd experiment with alternative ways of responding. This is
articularly relevant in psychosis where fearful beliefs can
e extreme and make real world tests very daunting.
rucially, however, the learning made in VR translates into
he real world. The power of VR inter-ventions thus far has
een most evident in the treatment of anxiety disorders
Freeman et al., 2017). A meta-analysis of 30 randomised 
ontrolled trials of VR exposure therapy showed a large 
ffect size compared to waitlist controls and equivalent 
ffects compared to in vivo exposure ther-apy (Carl et al., 







romising evidence is emerging for the use of VR treatments
n psychosis (Freeman et al., 2016; Pot-Kolder et al., 2018;
reeman, Lister et al., 2019). It is important to note that
he overwhelming majority of the VR interventions tested
o date have relied on a therapist being present to deliver
he psychological techniques, greatly limiting the scalability
f these treatments.
utomating therapy delivered in VR
e have automated the delivery of VR interventions
hrough the use of a virtual coach, who explains the
sychologi-cal principles and guides the person through the
reatment (Freeman et al., 2018; Freeman, Lister et al.,
019). This, coupled with the use of consumer VR
ardware, means provi-sion of cognitive therapy can be
ubstantially scaled up. Our first automated VR therapy, for
ear of heights, was shown in a randomised controlled tria
ith 100 participants to have a large effect size (d = 2.0;
reeman et al., 2018), exceeding that expected from
herapist-assisted exposure using real world heights (d =
.1; Wolitzky-Taylor, Horowitz, Powers & Telch, 2008). This
uggests automated VR therapy can be as effective, if not
ore effective, than treatments delivered in traditiona
ormats. Nonetheless, it may be that specific phobias are
ore tractable than the mental health difficul-ties seen in
econdary services. The next stage of our work has
herefore been to develop and test automated VR ther-apy
or more complex difficulties, starting with the highly
revalent anxious social withdrawal in psychosis.
argeting anxious social withdrawal in psychosis
any people with psychosis are socially withdrawn and iso-
ated, with significant consequences for both mental and
hysical health. Patients with psychosis are sedentary for
arge periods of the day (Stubbs, Williams, Gaughran, &
raig, 2016). Life expectancy is on average 14.5 years
horter (Hjorthøj, Stürup, McGrath, & Nordentoft, 2017),
ue to largely preventable conditions such as high blood
ressure, diabetes, and heart disease. Partly this physica
ll health reflects unhealthy lifestyles including inactivity.
ur view is that inactivity arises, at least in part, from
nxious avoidance. In a recent survey of 1800 patients with
on-affective psychosis in NHS services, two-thirds of
atients reported levels of anxious avoidance comparable 
o those with agoraphobia (Freeman, Taylor, Molodynski, & 
aite, 2019). The causes of this anxious withdrawal may be 
any: paranoia, threatening voices, social anxiety, 



















































































t  cope. Difficult experiences may have happened outside
too. However the end result is unfounded or exaggerated
fear cognitions (with a range in content). These fearful
cognitions lead to the avoidance of social situations, or
when this is not possible the use of in-situation defence
(safety-seeking) behaviours. These behaviours prevent the
receipt and pro-cessing of disconfirmatory information and
hence the fear cognitions persist. Overcoming anxious
avoidance requires a highly active treatment directly in the
troubling situations, with the dropping of defence
behaviours, so that patients can evaluate the fear
cognitions in the moment (Clark, 1999). Such an
intervention could be effectively delivered in VR.
The gameChange project
gameChange is a three-year project funded by the UK’s
National Institute for Health Research (NIHR). Led by
researchers at the University of Oxford and Oxford Health
NHS Foundation Trust, the project has collaborators from
many other organisations, including the Royal College of Art,
the McPin Foundation, NIHR MindTech, Oxford VR, and sev-
eral other NHS trusts. The project has four main objectives
spanning treatment development to implementation:
• to develop a powerful VR treatment—which is usable,
engaging, and scalable - targeting anxious avoidance of
social situations by patients with psychosis;
• to identify the barriers and facilitators for the implemen-
tation of the VR therapy and produce an implementation
plan;
• to conduct a multisite randomised controlled trial testing
the clinical effectiveness and cost effectiveness of the
gameChange VR therapy;
• and to create a commissioning case and commercialisa-
tion plan to enable the rolling out of this intervention
across the UK’s National Health Service.
This paper describes the development of the automated
VR therapy, which was carried out over the first 12 months 
of the project.
The design process
gameChange VR therapy was developed using a person-
centred design process. This is an iterative approach where
the end-user’s perspective and needs are incorporated into
all stages of the design process with the aim of creating an
easy to use, meaningful, and accessible treatment (Lyon &
Koerner, 2016). Designs had to reflect the needs of patients
with psychosis, whilst incorporating the psychological prin-
ciples of the treatment and adhering to the parameters of
the project (e.g. timetable, technical feasibility). The
design process was a collaboration between people with
lived experience of psychosis, clinical psychologists,
design-ers, and software developers. Overall responsibility
for final design decisions was held by the clinical
psychology team in Oxford, who co-ordinated input from 
different contribu-tors. The stages of the design process 
included the setting out of the initial design brief, 
workshops and individual ses-sions addressing key questions 







roduction of thirty-three workflows, a script for the
irtual therapist, prototypes of the scenarios to obtain
eedback, 3D modelling of the virtual environments,
reating and animat-ing the virtual characters, software
mplementation of the workflows, extensive user testing
evisions to the software and quality assurance procedures.
he treatment brief
ameChange built on a series of studies from our group
how-ing that VR: could elicit unfounded fearful thoughts
bout other people (e.g. Freeman et al., 2003); is safe to
se with patients with psychosis (e.g. Freeman, Pugh,
orontsova, Antley & Slater, 2010); and that it could be
uccessfully used in treatment for patients with psychosis
Freeman et al., 2016). Freeman and colleague’s (2016)
reatment study demonstrated that it is not simply
xposure to a trou-bling situation that is key for clinical
hange but actively testing out fears with the dropping of
efence behaviours. This approach follows the successful
eal-world behaviour experiments described by Clark (1999)
or the treatment of anxiety disorders, and is also
onsistent with the theory of inhibitory learning that
ndicates the benefits of a belief dis-confirmation approach
ver a habituation approach (Craske, Treanor, Conway,
bozinek, & Vervliet, 2014). Key learning about the
utomation of VR therapy was taken from two pre-vious VR
nterventions that we have developed: for treating the fear
f heights (Freeman et al., 2018) and persecutory delusions
Freeman, Lister et al., 2019). This previous work provided
he treatment structure, including 30 minute ses-sions,
raded levels of difficulty, and automation through the use
f a virtual coach. The virtual coach (in a virtual office)
ould explain the treatment rationale and then accom-
any the patient into the different simulations. We used
ur experience of developing intensive, short-term face-to-
ace treatments for psychosis focussed on clear, single
oals (e.g. Freeman et al., 2015). We planned to develop a
reatment of approximately a six session length and to
ncorporate practice tasks between sessions. Thus the
utline treatment brief was to target anxious avoidance in
sychosis, creating 6 scenarios with 5 levels of difficulty in
ach. Every level would provide an opportunity to test out
earful cognitions with defence behaviours dropped.
articipants would be guided through the treatment by a
irtual coach. This brief pro-vided a framework for the
reatment, but clearly detailed work was required
oncerning the environments to be devel-oped, the tasks
ithin them, the content of the scripts, and how tasks
ould be set between VR sessions.
he input of users
he expertise of people with lived experience of psy-
hosis was central to all design decisions. In total 53
eople with lived experience contributed to the design of
he gameChange therapy (with over 500 hours of input).
atient involvement was set up and supported by the McPin 
oundation, a mental health research charity that helps 
nvolve experts by experience in research. Participants were 
ecruited through adverts circulated in NHS services, social 
edia, and patient involvement groups. Participants varied 














































































































t  e deliberately encouraged involvement from individuals 
ceptical about VR.
From the outset a gameChange Lived Experience
dvisory Panel (LEAP) was set up consisting of ten people
ith lived experience of psychosis. The LEAP was recruited
venly from the five different centres in the UK that would
e taking part in the clinical trial (Bristol, Manchester,
ewcastle, Notting-ham, and Oxford). They provided
onsultation throughout design and development, initially
elping to define the six VR scenarios and later feeding into
he design of characters, the script, VR prototyping, and
he development of usability measures.
In addition to the LEAP, twelve design workshops were
un in London, Newcastle, Nottingham, Manchester, Bristo
nd Oxford. These included people with lived experience of
sychosis (n = 3-9 in each workshop). All workshops were
rranged and facilitated by a member of the McPin Founda-
ion, with longstanding expertise in supporting involvement
f those with mental health difficulties in research. A clini-
al psychologist was also always present to provide support
o participants if needed. In addition workshops were also
ttended by designers, and a member of the software
evel-opment team.
Each workshop had a specific set of design aims which
ncluded, for example, the choice of scenarios, the tasks
ompleted in each scenario, the coach’s appearance and
hat they said, background characters, and important sit-
ational triggers. For example participants described the
ypes of characters that were more challenging (e.g. men,
eenagers and groups of people), the importance of back-
round noise as a trigger for anxiety, and the tasks that are
articularly challenging e.g. queuing with people behind.
Following each workshop, designs and VR prototypes
ere developed and these were then tested at the sub-
equent workshop in a continuous, iterative process. In
he later stages of development, seventeen individual user
esting sessions were held to provide feedback on the
ameChange application.
Five workshops were also held with NHS staff in Bristol,
ottingham, Newcastle, Manchester and Oxford. Staff from
 range of different services and professional backgrounds.
hey provided feedback on the gameChange programme
including the scenarios) and how the intervention would fit
ithin the current care pathways.
cript development
he script included the dialogue of the virtual coach as
ell as other virtual characters in the scenarios and thus is
undamental to successful automation. The script needed
o effectively communicate psychological principles in an
ngaging and accessible way, as well as ensuring that the
herapy content was relevant and appropriate for a range
f different psychosis presentations. Key fears and
ssociated defence behaviours were identified and
ighlighted through-out the script. Preferences for the
ording of feedback and encouragement from the coach
as provided through the user workshops. The result of this 
terative process was an early draft of the script (100 
ages). The script was role-played in full, and feedback by 
sychologists, developers, and individuals with lived 









eedback. The feedback form these sessions was then
ncor-porated into the script. This process was repeated
hree times before reaching the final script, which was
hen reviewed by the LEAP who provided additiona
eedback.
cenario workflows
nce designs were finalised, the sequence of events, tim-
ngs, and the journey of the user through each VR scenario
as mapped out in detail using workflows. This ensured
hat designs were effectively translated into VR. Workflows
ere designed based on timed, real world role plays of
ach scenario. These visual flows were then implemented
n VR by the software development team. Thirty-three
orkflows define the logics of the gameChange application.
oftware development
oftware development was carried out by Oxford VR
www.oxfordvr.org), a spin-out company from the
niversity of Oxford. Their team included virtua
nvironment artists, character artists, animators, software
evelopers and audio engineers, many of whom were
ecruited from the games industry. The character
nimations were recorded with an infrared camera-based
otion capture system with the help of a team of
rofessional actors. Many of the voice lines were recorded
uring five extra sessions in a sound record-ing studio. Each
ersion of the therapy went through scrutiny by Oxford
R’s quality and assurance lead. The different scenario
rototypes were reviewed on a weekly basis by clinica
sychologists, who provided feedback back to the
evelopment team.
gameChange was certified as a Class I medical device in
onformity with the Essential Requirements of the
irective 93/42/EEC. The process involved evaluating risks,
oftware, usability, clinical safety and efficacy of the
pplication.
ameChange VR therapy
he design process led to the development of the auto-
ated VR treatment. An initial list of scenarios relevant to
atients was generated by the LEAP. This included: being
n the street; using public transport (e.g. trains, buses);
laces where you have to queue, such as banks or doctor’s
urgeries; shops and supermarkets; a pub or café; enclosed
paces such as a lift; open plan office spaces; waiting
ooms; job centres, hairdressers; and lectures. Some of
hese situa-tions had to be excluded, either because they
ould be too challenging to replicate in VR or because the
cenario highlighted was unrelated to anxious avoidance.
ach LEAP member was asked to select the three scenarios
hey con-sidered the most important. The reasons they
hought these were important were also recorded, so that
f, for exam-ple, a lift scenario was selected because it 
nvolves being enclosed then this aspect could be 
ncorporated in a dif-ferent scenario if necessary e.g. being 
nclosed in on a crowded bus. In this way, we attempted to 
nsure each ‘trig-ger’ was embedded in one of the final 
cenarios. The final six gameChange scenarios selected 
ere: a bus, a street, a café, a pub, a doctor’s waiting 
































what happens, for example, ‘try looking around and making 
eye contact with others and see what happens’. Secondly, 
events occur that require patients to drop defences that 
they may be using. For example, in the café a customerFig. 1 The six gameChange scenarios: (A) Street, (B) Bus, (C)
The VR therapy begins in the coach’s room where the
patient meets Nic, their virtual coach (see Fig. 2). Nic
explains how VR works and introduces the psychological
principles and aims of the treatment. One lived experience
advisor described Nic’s role as ‘‘not just the person who is
providing instructions, it is the person who is there to
reas-sure, not about the facts she is saying, but the trust
part. Yes, it’s about having someone who is there for you
in any situation, not someone who spouts facts at you. It’s
about not being alone, a sense of bond, understanding and
care. It’s helpful for her to say, ‘‘Whenever you need to
exit it is ok, I will be there whenever you leave’’. Patients
are asked to rate their confidence in managing everyday
situations before selecting the scenario they wish to try,
starting with level 1 and repeating levels when needed.
Patients then re-rate their confidence again at the session
end. Each session in VR lasts approximately 30 minutes (see
Fig. 3).
The gameChange scenarios
In each of the six scenarios, first level is relatively quiet
and empty, so that patients have the chance to learn the
essential elements of the situation. As patients progress
through the levels, the scenarios become busier and
noisier; other triggers of anxiety appear or become more
promi-nent, for example CCTV cameras, characters 
standing closer to the patient or blocking the exit, police 
officers, hooded teenagers and people looking at them. In 
each scenario, patients have to carry out key tasks such as 




, (D) Doctor’s waiting room, (E) Corner shop, and (F) Pub.
hese were specifically designed activate fearful cognitions
nd thus provide opportunities for the patient to test out
heir fears. Some tasks are shared across scenarios whilst
thers are unique and thus made the principal challenge
ithin that scenario (See Table 1).
In addition, the testing of fearful cognitions is prompted
n two ways. Throughout levels, Nic encourages patients to
est out their fears by doing something different and seeingig. 2 The virtual coach, Nic who walks patients through the 
ameChange therapy.
Fig. 3 The structure of the virtual reality treatment.
Table 1 The main challenges encountered in each scenario.
Challenges Scenarios
Café Pub Bus Doctor’s
surgery
Food shop Street
Make a request/order *
Stay in a situation
Give personal information
Unexpected event/erratic behaviour *
People looking towards you
Trapped/shut in *
Required to find an item *

























































a  Awkwardly quiet
* Denotes the principal challenge for the scenario.
eaves their wallet on the counter and the patient is asked
o shout after them across the café, drawing attention to
hemselves and prompting other characters to look at them,
hereby the patient has the experience of coping with this
ype of situation and they are thanked by the customer who
eft their wallet.
elivery
ameChange is an automated psychological therapy and
hus does not require a trained CBT therapist to deliver it.
ameChange can be delivered by any member of staff,
ho’s role would be to set up the equipment and provide
ncour-agement and support. All delivery staff are trained
o help the patient to get the most out of the programme.
s with all interventions regular supervision remains
mportant. Work-shops with staff and patients identified
eer support workers as well placed to deliver this
ntervention, as well as being delivered by assistant
sychologists and psychologists. Work-shops also suggested
ameChange could be of value at different stages of the
are pathway and could complement available treatments.
ameChange can be delivered using commercially available
R equipment. This equipment is portable and quick to set
p allowing gameChange to be delivered in clinic settings
r in people’s homes, as required.
sability testinghe gameChange design process aimed to develop a pow-
rful VR treatment targeting anxious avoidance that was 
seable and highly engaging. The success criterion set at 








ameChange as immersive, easy to use, and engaging. A
sability questionnaire was developed during the project.
ormal usability testing was carried out initially in the later
tages of development with five patients. Patients with
ived experience of psychosis completed a session of
ameChange VR therapy, providing feedback and
ompleting the usability questionnaire. A second usability
esting session was held with six patients when
evelopment was complete. The success criterion was
chieved at this session with all six patients rating
ameChange VR as immersive, easy to use, and engaging
see Table 2).
ext steps
ameChange VR therapy has been built and is currently
eing tested in a randomised controlled trial in five centres
n the UK. The trial protocol has been published (Freeman
t al., 2019b). The aim is to recruit 432 patients with
sychosis who are anxious going into everyday situations.
atients are randomised either to the VR therapy plus usua
are or to usual care only. The primary outcome measure is
voidance and anxiety in the real world using the Oxford
ehavioural Avoidance Task (Freeman et al., 2016), in
hich patients are asked to move through a hierarchy of
he situations they typically avoid, rating their anxiety at
ach step and stopping when the anxiety is too great.
econdary outcomes include activity levels measured by
ctigraphy;, psychiatric symptoms including depression and
uicidality, and qual-ity of life. The clinical trial will be 
ompleted in January 2021. In parallel with the trial, a 
rocess evaluation is being conducted to identify the 
acilitators and barriers to deliver-ing gameChange in the 
K’s National Health Service. After the extensive and 
ntensive design process that has been
Table 2 Results from usability testing sessions.
Usability testing 1 
(pre-completion)
(n = 5)
Usability testing 2 
(post-completion)
(n = 6)
Easy Difficult Easy Difficult
2 3 6 0
4 1 6 0
1. Knowing what to do in any given VR situation was. . .
2. Understanding the coach’s instructions was. . .
3. Carrying out an action (for example, use the
confidence rating scale, burst the bubbles) was. . .
5 0 6 0
5 0 6 0
4 1 6 0
4. Using the circles to move through the program was. . .
5. Learning what to do and how to do it was. . .
6. Remembering how to do things a second time was. . . 5 0 6 0
Agree Disagree Agree Disagree
3 2 6 0
4 1 6 0
3 2 6 0
7. When using the VR, I felt like I was in the situation.
8. When other people were there in the VR, I felt like I
was sharing the space with them.
9. I enjoyed using the treatment

































conducted to produce a highly engaging and useable auto-
mated treatment, these evaluation elements will provide a
thorough test of the gameChange VR therapy.
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